Retrospective cohort study demonstrates ticagrelor increases cardiovascular events in patients with ACS and CKD, suggesting caution in this population.
Key Points
Ticagrelor is associated with higher risks of myocardial infarction compared to clopidogrel in CKD patients.
Patients treated with ticagrelor showed significant higher rates of cardiovascular-related readmission than those on clopidogrel.
This retrospective cohort study used the TSOC ACS-DM registry to analyze data on diabetes and CKD patients.
Findings indicate that antiplatelet choice may significantly impact cardiovascular outcomes in high-risk populations.